Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
Sponsor: Instituto Nacional de Cancerologia de Mexico
This PHASE2/PHASE3 trial investigates Antiemetics and Antineoplastic Agents and is currently ongoing. Instituto Nacional de Cancerologia de Mexico leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto Nacional de Cancerologia de Mexico
For direct contact, visit the study record on ClinicalTrials.gov .